ChromaDex News

Express News | Chromadex Appoints Carlos Lopez as Senior Vice President, General Counsel

ReutersJul 22 08:34 ET

Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus

Seeking AlphaJul 19 14:40 ET

ChromaDex Appoints James Lee as Interim CFO

Seeking AlphaJul 17 06:39 ET

Express News | Chromadex Says Board Appointed James Lee As Interim CFO

BenzingaJul 16 16:15 ET

Express News | Chromadex Corp: Board Appointed James Lee as Co's Interim Chief Financial Officer

ReutersJul 16 16:13 ET

Express News | Chromadex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

ReutersJul 16 08:34 ET

H.C. Wainwright Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $6

H.C. Wainwright analyst Ram Selvaraju maintains $ChromaDex(CDXC.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 43.2% and a

Moomoo NewsJul 15 06:31 ET · Ratings

Buy Rating Affirmed for Chromadex on Niagen+ Launch and Market Potential

TipRanksJul 15 06:16 ET

When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?

Yahoo FinanceJul 12 14:12 ET

FDA Revokes Use of Brominated Vegetable Oil in Food

The Food and Drug Administration no longer allows the use of brominated vegetable oil as a food additive, finalizing a move the agency had signaled in November.

Dow JonesJul 2 16:47 ET

Express News | ChromaDex Joins Russell 2000 Index As Part Of Annual Reconstitution; Inclusion Effective July 1, 2024

BenzingaJul 1 08:34 ET

ChromaDex to Join Russell 2000 Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC),

BusinesswireJul 1 08:32 ET

Express News | Chromadex Corp: On June 19, Brianna Gerber, CFO Informed Co That She Will Be Resigning

ReutersJun 25 17:20 ET

ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial

ChromaDex (CDXC) said Monday a phase 2 trial showed the "promising effects" of nicotinamide riboside supplementation in people with peripheral artery disease. The data showed benefits of nicotinamide

MT NewswiresJun 24 10:20 ET

Express News | Chromadex Corp: Results From Phase II Clinical Study Show Promising Effects of Nr Supplementation for People With Peripheral Artery Disease (Pad)

ReutersJun 24 08:34 ET

Milestone Phase II Clinical Study Demonstrates Niagen, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals With Peripheral Artery Disease (PAD)

NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a

BusinesswireJun 24 08:32 ET

Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair

Yahoo FinanceJun 15 10:29 ET

Express News | ChromaDex Unveils Niagen+ With FDA Authorization; NRC To Be Available In IV, Shot, And Push Forms At Clinics Nationwide

BenzingaJun 13 08:34 ET

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen (Patented Nicotinamide Riboside Chloride or NRC)

Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion

BusinesswireJun 13 08:32 ET

ChromaDex Is Maintained at Buy by Roth MKM

ChromaDex Is Maintained at Buy by Roth MKM

Dow JonesJun 12 11:56 ET